|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have intercrossed mice with mammary-specific mutation of p53 with mice deficient in Amphiregulin in order to assess the requirement for Amphiregulin in the initiation and progression of both estrogen receptor-positive and estrogen receptor-negative mammary tumors.
|
31838731 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While recombinant AREG did not impact mammary tumour cell proliferation <i>in vitro</i> despite inducing a dose-dependent increase in phosphorylated EGFR, intranasal administration of AREG resulted in a ten-fold increase in pulmonary metastatic tumour burden <i>in vivo</i>.
|
30713780 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, the result from study in vivo showed that the silencing AREG expression by AREG knocked down inhibited tumor growth in nude mice.
|
31466817 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For validation studies, we utilized an independent set of meningioma tumor tissue samples (Grade I, <i>n</i> = 20; Grade II, <i>n</i> = 10; Grade III, <i>n</i> = 6), and found that the expressions of amphiregulin and Caspase3 are significantly increased in all grades of meningiomas either at the transcriptional or protein level, respectively.
|
31649887 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Production of AREG is triggered by DNA damage to stromal cells, which passively enter senescence in the tumor microenvironment (TME), a process that remarkably enhances cancer malignancy including acquired resistance mediated by EGFR.
|
31493351 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a mouse model of BRCA1-related BC, cancer-associated AhR and AREG control tumor growth and production of chemokines to attract monocytes and activate proangiogenic function of macrophages in the tumor microenvironment.
|
30733286 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, expression of amphiregulin promoted tumour growth, implicating causal relationship between the expression of IL13Rα2 and amphiregulin.
|
30718742 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among patients who received anti-EGFR antibody, response rates were significantly higher in AREG<sup>High</sup> than in AREG<sup>Low</sup> In the left-sided tumor group, overall survival was significantly longer in patients with high EREG levels than with low levels, whereas the right-sided tumor group showed no survival difference between them.
|
31519572 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary myoepithelial cells from nontumor-bearing AREG<sup>+/+</sup> mice underwent fluorescence-activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived from C57Bl/6 PyMT mammary tumors.
|
30367629 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This combined inhibition attenuated tumor growth in PDX and increased survival of PKT mice while reducing serum AREG levels.
|
30154150 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of YAP, TAZ and AREG was correlated with the volumetric dimensions of tumors on contrast-enhanced magnetic resonance imaging (ceMRI).
|
28430338 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Trop2+/AREG+ protein coexpression were associated with Tumor Node Metastasis (TNM) stage (χ<sup>2</sup> = 50.345, P < 0.001), tumor size (χ<sup>2</sup> = 40.349, P < 0.001), lymph node metastases (χ<sup>2</sup> = 26.481, P < 0.001), and distant metastases (χ<sup>2</sup> = 8.387, P = 0.039).
|
28256068 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
First, upstream molecules, including epiregulin (EREG) and amphiregulin (AREG), might play different roles according to their abnormal levels in tumor tissue and serum.
|
27422777 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EREG and AREG are strongly regulated by methylation, and their expression is associated with CIMP status and primary tumour site, which may explain the association of primary tumour site and EREG/AREG expression with anti-EGFR therapy efficacy.
|
27272216 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Molecular characteristics were correlated with response, progression-free survival (PFS), overall survival (OS). mRNA expression was evaluated using ROC-analysis in 192 tumors (AREG high n = 31 vs. low n = 161; EREG high n = 89 vs. low n = 103).
|
26284333 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To identify suitable ligands, we surveyed fluids from ovarian and lung cancer patients and found that amphiregulin (AREG) is the most abundant and generalized ligand secreted by advanced tumors.
|
25915843 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Amphiregulin (AREG), an epidermal growth factor receptor (EGFR) ligand, has been shown to be a downstream target of CRTC1-MAML2 fusion, and to play a role in tumor growth and survival in CRTC1-MAML2-positive MEC cell lines.
|
27393417 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Data were analysed by tumour RAS (KRAS/NRAS) and BRAF status, and baseline amphiregulin (AREG) expression.
|
27764839 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, TGF-β1 increases lymphangiogenic genes and amphiregulin expression in KRC PCCs but not in murine PCCs that lack SMAD4, and combinatorial targeting of the TGF-β type I receptor (TβRI) with LY2157299 and EGFR/HER2 with lapatinib suppresses tumor growth and metastasis in a syngeneic orthotopic model, and attenuates tumor lymphangiogenesis and angiogenesis while reducing lymphangiogenic genes and amphiregulin and enhancing apoptosis.
|
27267807 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The influence of epidermal growth factor (EGF), amphiregulin (AR), and epiregulin (EPR) on tumor cell proliferation and cetuximab response was evaluated by the addition of recombinant human (rh) proteins or by siRNA-mediated downregulation of the endogenous ligand production.
|
25677871 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Blocking AR/EGFR signaling in Tregs with Gefitinib also enhanced anti-tumor immunity and decreased tumor size in a mouse xenograft tumor model.
|
26451607 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification of AREG and PLK1 pathway modulation as a potential key of the response of intracranial 9L tumor to microbeam radiation therapy.
|
25382544 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mandatory tumor and serum samples were collected (N = 808; 58% to 99.8% were assessable), and amphiregulin, betacellulin, epidermal growth factor (EGF), transforming growth factor alpha, EGF receptor, HER2, HER3, insulin-like growth factor 1 receptor, PTEN, phosphorylated AKT, PIK3CA, CMYC, serum HER2 extracellular domain (sHER2), and FCγR were assessed using appropriate assays.
|
25332247 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stimulation with the EGF-like growth factor Amphiregulin (AREG) markedly enhanced Treg cell function in vitro, and in a colitis and tumor vaccination model we showed that AREG was critical for efficient Treg cell function in vivo.
|
23333074 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Amphiregulin (AREG), a target gene for Yes-associated protein (YAP), is a known oncogenic component of the Hippo pathway; however, the tumor-suppressive effect of RASSF1A on AREG in regard to regulation of the Hippo pathway remains unclear in HCC.
|
23594797 |
2013 |